Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravitreal triamcinolone for diffuse diabetic macular oedema.

S K Gibran1, A Cullinane, S Jungkim

  • 1Department of Ophthalmology, Cork University Hospital, Cork, Ireland. syedgibran@yahoo.com

Eye (London, England)
|July 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Equine influenza and air transport.

Equine veterinary education·2020
Same author

Measurement of Typhi Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency.

Clinical and experimental immunology·2018
Same author

The impact of different equine influenza vaccine products and other factors on equine influenza antibody levels in Thoroughbred racehorses.

Equine veterinary journal·2014
Same author

Report of the International Equine Influenza Roundtable Expert Meeting at Le Touquet, Normandy, February 2013.

Equine veterinary journal·2014
Same author

The potential impact of a single amino-acid substitution on the efficacy of equine influenza vaccines.

Equine veterinary journal·2014
Same author

Comparison of primary vaccination regimes for equine influenza: working towards an evidence-based regime.

Equine veterinary journal·2013

Intravitreal triamcinolone (IVTA) offers a temporary solution for diabetic macular oedema (DME) resistant to laser therapy. This treatment effectively reduces macular thickness and improves vision for about six months.

Area of Science:

  • Ophthalmology
  • Endocrinology

Background:

  • Diabetic macular oedema (DME) is a leading cause of vision loss in diabetic patients.
  • Conventional treatments like laser therapy are often insufficient for refractory cases.

Purpose of the Study:

  • To assess the efficacy of intravitreal triamcinolone acetonide (IVTA) in treating diffuse diabetic macular oedema (DME) unresponsive to laser therapy.

Main Methods:

  • A prospective case series of 38 eyes with refractory DME received a 4 mg intravitreal injection of triamcinolone acetonide.
  • Visual acuity (VA) and macular thickness via optical coherence tomography (OCT) were measured at baseline and at 1, 3, and 6 months post-injection.

Main Results:

  • Visual acuity improved significantly from baseline (0.905) to 0.605 at 1 month, 0.555 at 3 months, and 0.730 at 6 months.

Related Experiment Videos

  • Macular thickness decreased from a baseline of 418.7 microm to 276.9 microm at 1 month, 250.6 microm at 3 months, and 308.8 microm at 6 months.

    • Conclusions:

    • Intravitreal triamcinolone acetonide (IVTA) shows potential as a temporary treatment for refractory diabetic macular oedema (DME).
    • The treatment effectively reduces macular thickness and enhances visual acuity for approximately six months.
    • Further research is needed to determine the long-term safety of IVTA for DME management.